StreetInsider.com News Articles

Form S-3 Avalo Therapeutics, Inc.

Fri, 17 Jul 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26784278.html

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Tue, 07 Jul 2026 07:00:00 -0400

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

Tue, 07 Jul 2026 07:00:00 -0400

About Avalo Therapeutics

Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 06 Jul 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260706/26736721.html

Leerink Starts Avalo Therapeutics Inc. (AVTX) at Outperform

Mon, 06 Jul 2026 06:19:47 -0400

(Updated - July 6, 2026 6:19 AM EDT)

Leerink analyst Thomas Smith initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Outperform rating and a price target of $38.00.

The analyst comments "We are initiating coverage of Avalo Therapeutics (AVTX) with an Outperform rating and a $38 price target. AVTX is a clinical-stage biotechnology company developing IL-1β–based therapies for immune-mediated inflammatory diseases with significant unmet need, anchored by lead program abdakibart (AVTX-009) that has already generated positive, de-risking Phase 2 data in hidradenitis suppurativa (HS). Abdakibart is a high-affinity, IL-1β–specific monoclonal antibody with best-in-class potential that targets a genetically and biologically

Leerink Starts Avalo Therapeutics Inc. (AVTX) at Outperform

Mon, 06 Jul 2026 06:19:47 -0400

(Updated - July 6, 2026 6:19 AM EDT)

Leerink analyst Thomas Smith initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Outperform rating and a price target of $38.00.

Form 4 Avalo Therapeutics, Inc. For: Jun 30 Filed by: Jain Rita

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727578.html

Form 4 Avalo Therapeutics, Inc. For: Jun 30 Filed by: Lind Kevin Robert

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727579.html

Form 4 Avalo Therapeutics, Inc. For: Jun 30 Filed by: Philip Ron M

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727583.html

Form 4 Avalo Therapeutics, Inc. For: Jun 30 Filed by: Doyle Mittie

Thu, 02 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26727584.html

Avalo Therapeutics to join Russell 2000 and Russell 3000 indexes

Fri, 26 Jun 2026 07:00:19 -0400

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company, announced it will be added to the Russell 2000® Index and the Russell 3000® Index, effective after the close of U.S. equity markets on June 26, 2026.

The Russell 3000® Index tracks the performance of the largest 3,000 publicly traded U.S. companies, representing approximately 96% of the investable U.S. equity market. The Russell 2000® Index is a subset of the Russell 3000® and serves as a benchmark for U.S. small-cap equities.

The Russell indexes are used by investment managers and institutional managers for index funds and as benchmarks for active investment strategies.

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Fri, 26 Jun 2026 07:00:00 -0400

WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000^® Index and the broad-market Russell 3000^® Index, effective after the close of U.S. equity markets on June 26, 2026.

The Russell 3000^® Index measures the performance of the largest 3,000 publicly traded U.S. companies, representing approximately 96% of the investable U.S. equity market. The Russell 2000^® Index is a subset of the

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Fri, 26 Jun 2026 07:00:00 -0400

Form 4 Avalo Therapeutics, Inc. For: Jun 23 Filed by: Doyle Mittie

Thu, 25 Jun 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260625/26693578.html

Form 3 Avalo Therapeutics, Inc. For: Jun 23 Filed by: Philip Ron M

Thu, 25 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260625/26693560.html

Form 4 Avalo Therapeutics, Inc. For: Jun 23 Filed by: Philip Ron M

Thu, 25 Jun 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260625/26693571.html

Form 8-K Avalo Therapeutics, Inc. For: Jun 23

Tue, 23 Jun 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260623/26675725.html

Avalo Therapeutics adds Ron Philip to its board of directors

Tue, 23 Jun 2026 07:00:09 -0400

Avalo Therapeutics, Inc. (Nasdaq: AVTX) has appointed Ron Philip to its board of directors, the clinical-stage biotechnology company announced in a press release.

Philip brings more than 30 years of biopharmaceutical experience to the role. He currently serves as executive chair of CREATE Medicines. Previously, he served as chief executive officer of Orbital Therapeutics, where he led the company through its $1.5 billion acquisition by Bristol Myers Squibb.

Prior to Orbital Therapeutics, Philip held senior leadership positions at Spark Therapeutics, eventually becoming chief executive officer. In that role, he oversaw the commercial launch of LUXTURNA, an FDA-approved gene therapy, and was involved

Avalo Therapeutics Appoints Ron Philip to Board of Directors

Tue, 23 Jun 2026 07:00:00 -0400

WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits.

“We are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2

Avalo Therapeutics Appoints Ron Philip to Board of Directors

Tue, 23 Jun 2026 07:00:00 -0400

“We are thrilled to welcome Ron to the Board at this pivotal time for Avalo following our positive Phase 2

Form SCHEDULE 13G Avalo Therapeutics, Inc. Filed by: Commodore Capital LP

Thu, 18 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260618/26666518.html

Form 8-K Avalo Therapeutics, Inc. For: Jun 16

Tue, 16 Jun 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260616/26650383.html

AVALO Therapeutics adds anti-IL-1β antibody AVTX-010 to pipeline

Tue, 16 Jun 2026 07:02:58 -0400

Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced the advancement of AVTX-010, an engineered anti-IL-1β monoclonal antibody, into its pipeline, with an Investigational New Drug application planned for the first half of 2027.

The company said AVTX-010 is designed to extend dosing intervals compared to its lead asset, abdakibart, and is being considered for development in hidradenitis suppurativa as well as additional inflammatory disorders. Avalo also stated the new molecule has the potential to strengthen its intellectual property position.

Chief Executive Officer Garry Neil, MD, said the decision follows topline Phase 2 data from the abdakibart LOTUS trial and engagement with the U.S. Food

AVALO Therapeutics adds anti-IL-1β antibody AVTX-010 to pipeline

Tue, 16 Jun 2026 07:02:58 -0400

Chief Executive Officer Garry Neil, MD, said the decision follows topline Phase 2 data from the abdakibart LOTUS trial and engagement with the U.S. Food

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Tue, 16 Jun 2026 07:00:00 -0400

IND submission for AVTX-010 planned for the first half of 2027

WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders.

“Building on the strength of our abdakibart Phase 2 LOTUS topline data and our conviction in the IL-1β pathway, we believe developing a long-acting next-generation molecule